DDInter4 DDInter624
Synthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market.
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
Abarelix {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Metronidazole {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Efavirenz
Abarelix {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aripiprazole
Aripiprazole {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Efavirenz
Abarelix {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Metronidazole {u} (Compound) causes {v} (Side Effect) Hepatitis
Hepatitis {u} (Side Effect) is caused by {v} (Compound) Efavirenz
Abarelix {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Sulfamethoxazole {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 2C9 Inhibitors
Cytochrome P450 2C9 Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Efavirenz
Abarelix {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aripiprazole
Aripiprazole {u} (Compound) causes {v} (Side Effect) Hepatitis
Hepatitis {u} (Side Effect) is caused by {v} (Compound) Efavirenz
Abarelix {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Galantamine
Galantamine {u} (Compound) downregulates {v} (Gene) CCDC86
CCDC86 {u} (Gene) is downregulated by {v} (Compound) Efavirenz
Abarelix {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dasatinib
Dasatinib {u} (Compound) upregulates {v} (Gene) IKBKB
IKBKB {u} (Gene) is upregulated by {v} (Compound) Efavirenz
Abarelix {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fluconazole
Fluconazole {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 2C19 Inhibitors
Cytochrome P450 2C19 Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Efavirenz
Abarelix {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lopinavir
Lopinavir {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
acquired immunodeficiency syndrome {u} (Disease) is treated by {v} (Compound) Efavirenz
Abarelix {u} may lead to a major life threatening interaction when taken with {v} Iloperidone
Iloperidone {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Efavirenz
Abarelix may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Efavirenz (Compound)
Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Aripiprazole and Aripiprazole (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Efavirenz (Compound)
Abarelix may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole (Compound) causes Hepatitis (Side Effect) and Hepatitis (Side Effect) is caused by Efavirenz (Compound)
Abarelix may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole (Compound) is included by Cytochrome P450 2C9 Inhibitors (Pharmacologic Class) and Cytochrome P450 2C9 Inhibitors (Pharmacologic Class) includes Efavirenz (Compound)
Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Aripiprazole and Aripiprazole (Compound) causes Hepatitis (Side Effect) and Hepatitis (Side Effect) is caused by Efavirenz (Compound)
Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Galantamine and Galantamine (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) is downregulated by Efavirenz (Compound)
Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib (Compound) upregulates IKBKB (Gene) and IKBKB (Gene) is upregulated by Efavirenz (Compound)
Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole (Compound) is included by Cytochrome P450 2C19 Inhibitors (Pharmacologic Class) and Cytochrome P450 2C19 Inhibitors (Pharmacologic Class) includes Efavirenz (Compound)
Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Lopinavir and Lopinavir (Compound) treats acquired immunodeficiency syndrome (Disease) and acquired immunodeficiency syndrome (Disease) is treated by Efavirenz (Compound)
Abarelix may lead to a major life threatening interaction when taken with Iloperidone and Iloperidone (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Efavirenz (Compound)